Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
By J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. Petersen, C. Sable, N. Kartsonis, A. Ngai, Arlene F. Taylor and 3 more. Clinical Infectious Diseases, 2004
638 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases, Small Animals
View Paper: https://www.semanticscholar.org/paper/193a4897f215ab2d1fc5d41305f60ff96727706f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
In Small Animals
Citations in the corpus
- Aspergillus Infections in Transplant Recipients (2005, background): “Caspofungin has been evaluated in a multicenter, noncomparative study of 90 patients who failed treatment with or were intolerant to conventional amphotericin, lipid preparations of amphotericin, or azoles (178).”
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “of caspofungin and micafungin in the treatment of CNS aspergillosis [398, 438].”
- Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). (2007, background): “are lacking for use as primary therapy [5].”
- Aspergillus flavus: human pathogen, allergen and mycotoxin producer. (2007, background): “fumigatus in two salvage studies (Maertens et al., 2004; Denning et al., 2006).”
- Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, background): “A study of caspofungin for patients who are intolerant of or refractory to conventional therapy also demonstrated a favorable response rate of ∼40% [127].”